Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
BioTime Inc, Medical Equipment, Deal Details 12
Venture Financing 12
LifeMap Solutions Raises US$5 Million In Seed Financing 12
Partnerships 13
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 13
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 14
OncoCyte Expands Co-Development Agreement with Wistar Institute 15
BioTime Enters Into Distribution Agreement With USCN Life Science 16
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 17
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 18
BioTime Enters Into Option Licensing Agreement With USCN Life Science 20
Equity Offering 21
BioTime Completes Public Offering of Shares for USD28.8 Million 21
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 23
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
BioTime to Raise up to USD25 Million in Private Placement of Shares 27
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 28
OncoCyte Raises USD3.2 Million in Private Placement of Units 29
OncoCyte Raises USD7.3 Million in Private Placement of Units 30
BioTime Raises USD5 Million in Private Placement of Shares 31
BioTime Raises USD20.4 Million in Private Placement of Shares 32
OncoCyte Raises USD3.3 Million in Private Placement of Shares 34
BioTime Completes Private Placement Of Shares For US$6.4 Million 35
BioTime Announces Public Offering Of Shares For Up To US$15 Million 36
BioTime Completes Public Offering Of Shares For US$3.5 Million 37
BioTime Completes Private Placement Of Units For US$9 Million 38
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 39
BioTime Announces Private Placement Of Common Stock 41
BioTime Completes Private Placement For US$3.6 Million 42
Acquisition 43
OrthoCyte Completes Acquisition Of Glycosan BioSystems 43
BioTime Inc – Key Competitors 45
BioTime Inc – Key Employees 46
BioTime Inc – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 48
Recent Developments 49
Financial Announcements 49
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 49
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 51
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 53
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 55
Feb 21, 2017: BioTime Reports Pro Forma Gain on Deconsolidation of OncoCyte Subsidiary 58
Nov 03, 2016: BioTime Reports Third Quarter Results and Recent Clinical Progress 59
Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments 61
May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 63
Corporate Communications 66
Jul 13, 2017: BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery 66
Feb 07, 2017: BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel 67
Oct 31, 2016: BioTime Appoints Industry Veteran Jim Knight as Senior Vice President, Head of Corporate Development 68
Product News 69
May 11, 2017: BioTime Presents Retinal Restoration Data at ARVO 69
Aug 15, 2016: BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine 70
Jun 28, 2016: Mount Sinai Launches Mobile Healthcare App Developed with LifeMap Solutions, a subsidiary of BioTime 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
BioTime Inc, Medical Equipment, Key Facts, 2016 2
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
BioTime Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
BioTime Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
BioTime Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
BioTime Inc, Deals By Market, 2011 to YTD 2017 9
BioTime Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
LifeMap Solutions Raises US$5 Million In Seed Financing 12
OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx 13
OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test 14
OncoCyte Expands Co-Development Agreement with Wistar Institute 15
BioTime Enters Into Distribution Agreement With USCN Life Science 16
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 17
OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology 18
BioTime Enters Into Option Licensing Agreement With USCN Life Science 20
BioTime Completes Public Offering of Shares for USD28.8 Million 21
OncoCyte Plans to Raise up to USD50 Million in Public Offering of Securities 23
OncoCyte Raises USD5.7 Million in Private Placement of Shares upon Exercise of Warrants 24
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 25
BioTime to Raise up to USD25 Million in Private Placement of Shares 27
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 28
OncoCyte Raises USD3.2 Million in Private Placement of Units 29
OncoCyte Raises USD7.3 Million in Private Placement of Units 30
BioTime Raises USD5 Million in Private Placement of Shares 31
BioTime Raises USD20.4 Million in Private Placement of Shares 32
OncoCyte Raises USD3.3 Million in Private Placement of Shares 34
BioTime Completes Private Placement Of Shares For US$6.4 Million 35
BioTime Announces Public Offering Of Shares For Up To US$15 Million 36
BioTime Completes Public Offering Of Shares For US$3.5 Million 37
BioTime Completes Private Placement Of Units For US$9 Million 38
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million 39
BioTime Announces Private Placement Of Common Stock 41
BioTime Completes Private Placement For US$3.6 Million 42
OrthoCyte Completes Acquisition Of Glycosan BioSystems 43
BioTime Inc, Key Competitors 45
BioTime Inc, Key Employees 46
BioTime Inc, Subsidiaries 47
BioTime Inc, Joint Venture 48